AstraZeneca PLC
AZN69.570USD
+0.019+0.03%
收盘 04/25, 16:00（美东）报价延迟15分钟
215.74B总市值
30.67市盈率 TTM
关于 AstraZeneca PLC 公司
阿斯利康是一家以科学为主导的生物制药公司。该公司发现、开发和商业化肿瘤、罕见病和生物制药领域的处方药，包括心血管、肾脏和代谢、呼吸和免疫学以及疫苗和免疫疗法。其主要销售的肿瘤产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Zoladex、Faslodex 等。其罕见病产品包括 Soliris、Ultomiris、Strensiq 和 Kanuma。其生物制药产品包括 Farxiga、Crestor、Breztri 等。其在研疫苗候选药物 IVX-A12 针对呼吸道合胞病毒和人类偏肺病毒。其肿瘤候选药物包括针对转移性去势抵抗性前列腺癌的前列腺特异性膜抗原的 FPI-2265，目前处于 II 期试验阶段。该公司还发现、开发和制造 T 细胞受体疗法。其生产的 Eneboparatide 是一种正在研究的治疗肽。
公司简介
公司代码AZN
公司名称AstraZeneca PLC
上市日期Sep 21, 2007
成立日期1992
CEOMr. Marc Dunoyer
员工数量94300
证券类型Ordinary Share
年结日Sep 21
公司地址1 Francis Crick Avenue
城市CAMBRIDGE
上市交易所London Stock Exchange
国家United Kingdom
邮编CB2 0AA
电话442073045000
网址https://www.astrazeneca.com/
公司代码AZN
上市日期Sep 21, 2007
成立日期1992
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Aradhana Sarin, M.D.
Ms. Aradhana Sarin, M.D.
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Farxiga
7.66B
15.03%
Tagrisso
6.58B
12.92%
Imfinzi
4.72B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.13B
6.14%
Other
24.93B
48.95%
地区USD
名称
营收
占比
United States
21.81B
42.81%
China
6.42B
12.60%
United Kingdom
4.74B
9.31%
Other European Countries
3.66B
7.19%
Japan
3.45B
6.78%
Other
10.86B
21.32%
业务
地区
业务USD
名称
营收
占比
Farxiga
7.66B
15.03%
Tagrisso
6.58B
12.92%
Imfinzi
4.72B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.13B
6.14%
Other
24.93B
48.95%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
PRIMECAP Management Company
1.32%
Capital International Investors
1.21%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.09%
T. Rowe Price International Ltd
0.86%
Other
94.33%
持股股东
股东统计
占比
PRIMECAP Management Company
1.32%
Capital International Investors
1.21%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.09%
T. Rowe Price International Ltd
0.86%
Other
94.33%
股东类型
股东统计
占比
Investment Advisor
9.45%
Investment Advisor/Hedge Fund
5.99%
Hedge Fund
0.96%
Research Firm
0.88%
Bank and Trust
0.15%
Pension Fund
0.04%
Venture Capital
0.02%
Family Office
0.02%
Family Office
0.02%
Other
82.47%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
1957
546.41M
17.61%
+3.36M
2024Q4
1985
546.17M
17.61%
+11.21M
2024Q3
1920
519.95M
16.76%
-17.37M
2024Q2
1910
530.80M
17.12%
-10.51M
2024Q1
1865
523.00M
16.86%
-21.20M
2023Q4
1838
520.78M
16.79%
-27.28M
2023Q3
1815
530.17M
17.10%
-14.80M
2023Q2
1812
525.36M
16.94%
-28.74M
2023Q1
1803
534.31M
17.23%
-35.06M
2022Q4
1806
550.27M
17.75%
-33.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
PRIMECAP Management Company
41.02M
1.32%
-960.52K
-2.29%
Dec 31, 2024
Capital International Investors
37.51M
1.21%
+686.01K
+1.86%
Dec 31, 2024
Wellington Management Company, LLP
37.04M
1.19%
-208.20K
-0.56%
Dec 31, 2024
T. Rowe Price Associates, Inc.
33.74M
1.09%
-3.07M
-8.34%
Dec 31, 2024
T. Rowe Price International Ltd
26.61M
0.86%
+530.22K
+2.03%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.15M
0.59%
-1.10M
-5.70%
Dec 31, 2024
Managed Account Advisors LLC
16.43M
0.53%
-1.13M
-6.44%
Dec 31, 2024
Jennison Associates LLC
15.43M
0.5%
+466.42K
+3.12%
Dec 31, 2024
Sanders Capital, LLC
15.19M
0.49%
+212.30K
+1.42%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
12.04M
0.39%
+161.77K
+1.36%
Feb 28, 2025
查看更多
持股ETF
更新时间: 4月5日 周六
更新时间: 4月5日 周六
机构名称
占比
First Trust WCM International Equity ETF
6.02%
Amplify Weight Loss Drug & Treatment ETF
5.95%
Parnassus Value Select ETF
5.6%
VanEck Pharmaceutical ETF
5.09%
Roundhill GLP-1 & Weight Loss ETF
4.88%
ProShares Ultra Nasdaq Biotechnology
4.27%
Invesco Nasdaq Biotechnology ETF
4.25%
Invesco QQQ Low Volatility ETF
4.19%
PGIM Jennison Focused Value ETF
3.39%
Global X Aging Population ETF
2.87%
查看更多
First Trust WCM International Equity ETF
占比6.02%
Amplify Weight Loss Drug & Treatment ETF
占比5.95%
Parnassus Value Select ETF
占比5.6%
VanEck Pharmaceutical ETF
占比5.09%
Roundhill GLP-1 & Weight Loss ETF
占比4.88%
ProShares Ultra Nasdaq Biotechnology
占比4.27%
Invesco Nasdaq Biotechnology ETF
占比4.25%
Invesco QQQ Low Volatility ETF
占比4.19%
PGIM Jennison Focused Value ETF
占比3.39%
Global X Aging Population ETF
占比2.87%
分红派息
近5年累计派现
20.90B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Jul 30, 2020
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020
Aug 14, 2020
Sep 14, 2020
Aug 13, 2020
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据